MOUNT PLEASANT, S.C., Sept. 7 /PRNewswire-FirstCall/ -- Maxxon, Inc. (OTC Pink Sheets: MXON - News; “Maxxon”), a growing medical products designer, manufacturer, and distributor concentrating on innovative Safety-engineered medical devices (SEMDs) that will have a price advantage over many competitors in the SEMDs arena, is pleased to announce the completion of its 3cc ReVac Safety Syringe (“ReVac”) 5000 pc samples.
Some of the samples will be used for the FDA 510K application process; the procedure will be similar to the tests performed by Maxxon’s partner Globe Med Tech (“Globe”) over the past several months. As part of the application process, outside FDA approved testing facilities will be selected and the results will be included along with the application.
Andy Hu, CTO of Maxxon, said, “The samples will be shipped from China and our expectations of wide acceptance in this marketplace couldn’t be higher. Our engineers have performed additional tests over the past 2 weeks to assure the clinical test will be passed. The clinical trial will consist of 10 nurses trying 50 to 75 syringes, each. The purpose is to guarantee the safety of syringe. Our engineers have achieved the ultimate quality goal and the failure rate will be less than 1%.”
The rest of the 5000 pc samples will be used for market awareness and to introduce future customers, distributors, and medical sales organizations to the ReVac product.
“There has been such a global interest in our 3cc ReVac Safety Syringe and now we are finally ready to show them off,” stated Ron Wheet, President and CEO, Maxxon, Inc.
Maxxon will continue to move their suite of products forward including the 1cc, 5cc, 10cc ReVac Safety Syringes, as well as the ReVac IV Safety Catheter. Maxxon, along with partner Globe, will also progress on the manufacturing and distribution of their patented Auto Retractable Safety Scalpels. The completion of the 3cc ReVac samples should make it easier to raise the necessary capital to finish these other products and bring them to the market.
About Maxxon
Maxxon operates in the Safety-engineered medical devices (SEMDs) arena. Its products include the ReVac Safety Syringe, Auto Retractable Safety Scalpel with Permanent Lock and the Auto Retractable Safety IV Catheter. The world market for SEMDs was projected to exceed $1.6 billion last year and is forecast to maintain, near term, a 20% annual growth rate. In the U.S., the safety needles and syringes market is expected to generate approximately $693 million in revenues in 2006, representing 66% of the total needles and syringes market a compound annual growth rate of 21.7%. The Theta Report estimated the number of needles and syringes sold in the U.S. and international market, combined, should exceed 20 billion units in 2006.
The company feels that it will be able to market itself as a growing SEMDs designer, manufacturer and distributor that creates innovative SEMDs, which it believes will have a price advantage over its competitors. Currently, Johnson & Johnson, Becton Dickinson and Kendall Healthcare, a Tyco International Company, are among the market leaders, but a quick product demonstration on our website will show that Maxxon is a strong alternative. Maxxon is prepared to distribute the product directly, or would consider a strategic alliance with a major distributor, upon US FDA 510K Application acceptance.
The Needlestick Safety and Prevention Act became law on November 6, 2000, Public Law 106-430. To meet the requirements of this act, OSHA revised the Bloodborne Pathogen Standard 1910.1030 effective April 18, 2001. The revised Standard requires that Employers use effective engineering controls, including safer medical devices in order to reduce the risk of injury from needlesticks and other sharp medical instruments.
OSHA estimates that 8 million workers in the health care industry and related occupations are at risk of occupational exposure to bloodborne pathogens, including HIV, Hepatitis (Carried by at least 4 million Americans) and others. In fact, a typical needle can harbor more than 20 diseases. According to the American Hospital Association, one case of serious infection by bloodborne pathogens can soon add up to $1 million or more in expenditures for testing follow-up, lost time, and disability payments.
Maxxon’s 3cc safety syringe is designed as a single-handed, vacuum- operated safety syringe that retracts the used needle into the syringe after use.
For more information on Maxxon, please go to http://www.maxxoninc.com .
About Globe Medical Tech
Globe Medical Tech, Inc. is a high-tech medical safety and drug delivery products developer and manufacturer based in Houston, Texas, with a clean-room manufacturing presence in China. Globe has marketed its products in the U.S. and around the world, providing the medical industry with innovative low-cost, high-quality medical products. Globe’s team has accumulated valuable integration experience for medical devices, while establishing itself as a cost effective operator in the medical device industry. Whether under the company’s brand name, or under a private label, Globe has a history of effectively integrating patent development, research, and engineering design capabilities.
For more information on Globe, please go to http://www.globemedtech.com .
This press release contains some forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in Maxxon’s SEC filings.
Gabe Sandler Sandler communications 866-772-0118
Source: Maxxon, Inc.